Biodesix to sell $55M in stock

LOUISVILLE — Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that specializes in developing tools to detect lung disease, expects to raise about $55 million through stock sales. 

The company plans a public offering of nearly 17.4 million common shares and a private sale of 760,857 shares of preferred stock. 

“Certain members of management, certain of our directors and funds affiliated with these directors are participating in the concurrent private placement,” Biodesix said in a regulatory disclosure.

SPONSORED CONTENT

Exploring & expressing grief

Support groups and events, as well as creative therapies and professional counseling, are all ways in which Pathways supports individuals dealing with grief and loss.

TD Cowen, William Blair and Canaccord Genuity are acting as joint bookrunning managers for the stock sales.